BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1492223)

  • 1. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
    Greco FA; Johnson DH; Hainsworth JD
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Johnson DH; Greco FA
    Cancer; 1991 Jan; 67(1 Suppl):310-4. PubMed ID: 1984833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Johnson DH; Greco FA
    Semin Oncol; 1992 Apr; 19(2 Suppl 5):54-7; discussion 58. PubMed ID: 1384145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
    Hainsworth JD; Johnson DH; Greco FA
    J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
    Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
    J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
    Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
    Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary.
    Voog E; Merrouche Y; Trillet-Lenoir V; Lasset C; Peaud PY; Rebattu P; Negrier S
    Am J Clin Oncol; 2000 Dec; 23(6):614-6. PubMed ID: 11202809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Dial TW; Greco FA
    Am J Clin Oncol; 1988 Apr; 11(2):138-45. PubMed ID: 2451881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.
    Greco FA; Hainsworth JD
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):77-82. PubMed ID: 7992071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.
    Raber MN; Faintuch J; Abbruzzese JL; Sumrall C; Frost P
    Ann Oncol; 1991 Jul; 2(7):519-20. PubMed ID: 1911461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.
    van der Gaast A; Verweij J; Planting AS; Hop WC; Stoter G
    J Clin Oncol; 1995 Jul; 13(7):1720-5. PubMed ID: 7541451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinoma of unknown primary: identification of a treatable subset?
    van der Gaast A; Verweij J; Henzen-Logmans SC; Rodenburg CJ; Stoter G
    Ann Oncol; 1990; 1(2):119-22. PubMed ID: 1706613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.
    Saghatchian M; Fizazi K; Borel C; Ducreux M; Ruffié P; Le Chevalier T; Théodore C
    Ann Oncol; 2001 Apr; 12(4):535-40. PubMed ID: 11398889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic carcinoma of uncertain primary site: a retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE).
    de Campos ES; Menasce LP; Radford J; Harris M; Thatcher N
    Cancer; 1994 Jan; 73(2):470-5. PubMed ID: 8293415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study.
    Briasoulis E; Tsavaris N; Fountzilas G; Athanasiadis A; Kosmidis P; Bafaloukos D; Skarlos D; Samantas E; Pavlidis N
    Oncology; 1998; 55(5):426-30. PubMed ID: 9732220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
    Motzer RJ; Rodriguez E; Reuter VE; Bosl GJ; Mazumdar M; Chaganti RS
    J Clin Oncol; 1995 Jan; 13(1):274-82. PubMed ID: 7799031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.
    Hainsworth JD; Greco FA
    Semin Oncol; 1993 Jun; 20(3):279-86. PubMed ID: 8503024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of testicular cancer: a new and improved model.
    Einhorn LH
    J Clin Oncol; 1990 Nov; 8(11):1777-81. PubMed ID: 1700077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of recurrent and metastatic head and neck cancer with cisplatin/etoposide/bleomycin.
    Osoba D; Band PR; Connors JM; Goldie JH; Knowling MA; Fetherstonhaugh EM
    Semin Oncol; 1992 Apr; 19(2 Suppl 5):25-9; discussion 30-1. PubMed ID: 1384140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.